Detection of ALK expression in non-small-cell lung cancer with ALK gene rearrangements - comparison of multiple immunohistochemical methods

Histopathology

Volumn 65, Issue 4, 2014, Pages 539-548

  Zwaenepoel, Karen ^a   Van Dongen, Amber ^a   Lambin, Suzan ^a   Weyn, Christine ^a   Pauwels, Patrick ^a,b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Anaplastic lymphoma kinase; Fluorescence in situ hybridization; Immunohistochemistry; Non small cell lung cancer

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; PROTEIN TYROSINE KINASE;

ARTICLE; BRONCHUS BIOPSY; CELLULAR DISTRIBUTION; DIAGNOSTIC TEST ACCURACY STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIMIT OF DETECTION; MACROPHAGE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; COMPARATIVE STUDY; GENE TRANSLOCATION; GENETICS; IMMUNOLOGY; LUNG TUMOR; METABOLISM; PROCEDURES;

CARCINOMA, NON-SMALL-CELL LUNG; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSLOCATION, GENETIC;

EID: 84911805945     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12414     Document Type: Article

References (27)

1. Planchard D. Identification of driver mutations in lung cancer: first step in personalized cancer. Target Oncol. 2013; 8; 3-14.
2. Paez JG, Jänne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304; 1497-1500.
3. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13; 239-246.
4. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010; 363; 1693-1703.
5. Camidge DR, Bang YJ, Kwak EL et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012; 13; 1011-1019.
6. Lindeman NI, Cagle PT, Beasley MB et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J. Mol. Diagn. 2013; 15; 415-453.
7. Takeuchi K, Choi YL, Soda M et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin. Cancer Res. 2008; 14; 6618-6624.
8. Mino-Kenudson M, Chirieac LR, Law K et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin. Cancer Res. 2010; 16; 1561-1571.
9. Takeuchi K, Choi YL, Togashi Y et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin. Cancer Res. 2009; 15; 3143-3149.
10. Peters S, Taron M, Bubendorf L et al. Treatment and detection of ALK-rearranged NSCLC. Lung Cancer 2013; 81; 145-154.
11. Thunnissen E, Bubendorf L, Dietel M et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch. 2012; 461; 245-257.
12. Minca EC, Portier BP, Wang Z et al. ALK status testing in non-small cell lung carcinoma: correlation between ultrasensitive IHC and FISH. J. Mol. Diagn. 2013; 15; 341-346.
13. Tuononen K, Sarhadi VK, Wirtanen A et al. Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by FISH, immunohistochemistry, and real-time RT-PCR: a comparison of four methods. Biomed. Res. Int. 2013; 2013; 757490.
14. Sholl LM, Weremowicz S, Gray SW et al. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J. Thorac. Oncol. 2013; 8; 322-328.
15. Martinez P, Hernández-Losa J, Montero MÁ et al. Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. PLoS ONE 2013; 8; e52261.
16. Conklin CM, Craddock KJ, Have C et al. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J. Thorac. Oncol. 2013; 8; 45-51.
17. Park HS, Lee JK, Kim DW et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 2012; 77; 288-292.
18. Paik JH, Choe G, Kim H et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J. Thorac. Oncol. 2011; 6; 466-472.
19. Yang P, Kulig K, Boland JM et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J. Thorac. Oncol. 2012; 7; 90-97.
20. Salido M, Pijuan L, Martínez-Avilés L et al. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J. Thorac. Oncol. 2011; 6; 21-27.
21. Stein H, Foss HD, Dürkop H et al. CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000; 96; 3681-3695.
22. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448; 561-566.
23. Kim H, Yoo SB, Choe JY et al. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J. Thorac. Oncol. 2011; 6; 1359-1366.
24. Inamura K, Takeuchi K, Togashi Y et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod. Pathol. 2009; 22; 508-515.
25. Atkins D, Reiffen KA, Tegtmeier CL et al. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J. Histochem. Cytochem. 2004; 52; 893-901.
26. Lee JA, Shaheen M, Walke T et al. Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy. Exp. Rev. Pharmacoecon. Outcomes Res. 2011; 11; 325-341.
27. Lee JA, Bubendorf L, Stahel R et al. Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives. Exp. Rev. Anticancer Ther. 2013; 13; 625-636.